Biotech Values

[kakalak]

Thanks, BioWatch. DNDN is a calculated gamble.

If Provenge gets the nod--DNDN could quadruple to $16 based on a 4 times projected sales of $500 million in the first year.

If it is rejected--I take a 50% hit and have to wait another 18 months or so for the other 500 patient trial they are doing to be completed.

$12 upside

$2 downside.

My assumptions, of course.